Since 2022, Dr. Tolikas has held the senior vice president and chief innovation officer role at Dana-Farber Cancer Institute. She leads the Belfer Office for Dana-Farber Innovations, where she transforms the institute’s discoveries into real-world impact and oversees Binney Street Capital, Dana-Farber’s venture fund. With more than 20 years of experience building technology-based organizations, Dr. Tolikas ensures that advances made in Dana-Farber’s laboratories move effectively into the clinic, thus accelerating the pace at which new therapies reach patients worldwide. In the past three years, Dana-Farber executed over 200 licensing agreements in cancer therapeutics and diagnostics, forging partnerships with industry and startups to deliver breakthroughs to patients. Her work is central to Dana-Farber’s strategy of enabling innovation, building partnerships and creating pathways that directly translate research breakthroughs into patient benefit. Prior to joining Dana-Farber, Dr. Tolikas was CEO of the Wyss Center for Bio and Neuroengineering in Geneva, where she advanced neurotechnology development and commercialization. She also contributes to advisory boards and committees including CancerX, BIH Center for Regenerative Therapies in Berlin, and Institut Curie in Paris.
